Review summary
Teaching objective: Recognize and manage the harm of high-dose estrogen given to a 40-year-old gay man without his free and informed consent: evaluate gynecomastia as the EAA 2019 guideline advises (history, breast and testicular examination, testosterone, estradiol, LH, FSH, prolactin, SHBG, hCG, AFP, liver, kidney, and thyroid tests, scrotal ultrasound, breast imaging only if the examination is equivocal), name the cause as iatrogenic, stop the exposure, monitor recovery of the hypothalamic-pituitary-gonadal axis without testosterone therapy while it recovers, protect bone health, and offer surgery if gynecomastia persists; treat a moderate depressive episode with measurement-based care, gay-affirming psychotherapy, and an antidepressant only if he chooses one, with a structured suicide-risk assessment, a safety plan, and the 988 Lifeline; offer HIV and STI testing and a PrEP discussion as routine adult care with his consent; and practise LGBTQ-affirming primary care. Sexual orientation is recorded as part of his social history, never as a problem, and every test and treatment requires his free, informed consent.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| 23 June 1912 | Born in Paddington, London. | CLM-0001 |
| 1951 | Training for long-distance running around Wilmslow. | CLM-0002 |
| 31 March 1952 | Tried for gross indecency; accepts a year of oestrogen treatment instead of prison; loses his security clearance. | CLM-0003, CLM-0004, CLM-0005, CLM-0007, CLM-0008 |
| November 1952 | Decides to see a psychiatrist again and begins Jungian analysis. | CLM-0006 |
| 7 June 1954 | Dies at his home in Wilmslow; the inquest verdict, suicide, is later disputed. | CLM-0009, CLM-0010, CLM-0011 |
| 10 September 2009 | The Prime Minister apologises on behalf of the government. | CLM-0012 |
| 24 December 2013 | Posthumous royal pardon. | CLM-0013 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Alan Mathison Turing was born on 23 June 1912 in a nursing home in Paddington, London. | confirmed | Hodges A. Alan Turing (overview biography, revised from the Oxford Dictionary of National Biography entry) supports O'Connor JJ, Robertson EF. Alan Mathison Turing. MacTutor History of Mathematics supports |
| D | He was a long-distance runner: he built his strength in cross-country running, was known for running to scientific meetings, and in 1951 was still training for long-distance running on the roads around Wilmslow, where he had bought his first house. | confirmed | Hodges A. Alan Turing (overview biography, revised from the Oxford Dictionary of National Biography entry) supports Hodges A. The Alan Turing Internet Scrapbook: Non-linear Life supports |
| D | After reporting a burglary at his home in 1952 he was arrested over a relationship with another man and tried on 31 March 1952 for "gross indecency"; rather than go to prison he accepted, for a year, oestrogen treatment intended to neutralise his libido. Same-sex relations between men were then a crime in England; the treatment was imposed as the alternative to a prison sentence, not chosen as care. |
confirmed | Hodges A. Alan Turing (overview biography, revised from the Oxford Dictionary of National Biography entry) supports O'Connor JJ, Robertson EF. Alan Mathison Turing. MacTutor History of Mathematics supports Pease R. Alan Turing: Inquest's suicide verdict 'not supportable'. BBC News, 23 June 2012 supports |
| D | His biographer Andrew Hodges writes that the drug was probably stilboestrol, a synthetic oestrogen; the 2009 government statement and other sources describe the treatment as a series of injections of female hormones. The exact preparation and route are not settled in the sources read. |
probable | Hodges A. The Alan Turing Internet Scrapbook: Defiant until death supports Gordon Brown issues apology for treatment of Alan Turing supports Hodges A. Alan Turing (overview biography, revised from the Oxford Dictionary of National Biography entry) supports |
| D | Hodges describes the injurious and humiliating effect of the hormones on his body; it is often repeated that the treatment made him grow breasts, though he is known to have mentioned this only once. Breast growth (gynecomastia) is an expected effect of high-dose oestrogen in a man. |
probable | Hodges A. The Alan Turing Internet Scrapbook: Defiant until death supports Pease R. Alan Turing: Inquest's suicide verdict 'not supportable'. BBC News, 23 June 2012 supports |
| D | In a letter of 23 November 1952 he wrote that he had decided to have "another, and rather more co-operative go at a psychiatrist"; this was Jungian analysis with a refugee analyst, and he became very enthusiastic about it and wrote down all his dreams. Seeking analysis is documented; no psychiatric diagnosis is recorded in the sources read. |
confirmed | Hodges A. The Alan Turing Internet Scrapbook: Defiant until death supports |
| D | His conviction led to the removal of his security clearance, so that he could no longer work for Government Communications Headquarters as he had since the war. | confirmed | Royal pardon for WW2 code-breaker Dr Alan Turing supports |
| D | After the trial he returned to a wide range of academic work, including morphogenesis, quantum theory, and relativity, at Manchester University. | confirmed | O'Connor JJ, Robertson EF. Alan Mathison Turing. MacTutor History of Mathematics supports Pease R. Alan Turing: Inquest's suicide verdict 'not supportable'. BBC News, 23 June 2012 supports |
| D | He died on 7 June 1954 at his home in Wilmslow, Cheshire, of cyanide poisoning, and the coroner's verdict was suicide. | confirmed | Hodges A. Alan Turing (overview biography, revised from the Oxford Dictionary of National Biography entry) supports O'Connor JJ, Robertson EF. Alan Mathison Turing. MacTutor History of Mathematics supports Pease R. Alan Turing: Inquest's suicide verdict 'not supportable'. BBC News, 23 June 2012 supports |
| R | In 2012 Professor Jack Copeland argued that the inquest evidence would not today support a suicide verdict, that friends had described him as cheerful in the days before he died, and that accidental inhalation of cyanide from a home electrolysis experiment was equally likely. A retrospective challenge to the inquest finding; the cause of death remains disputed. |
disputed | Pease R. Alan Turing: Inquest's suicide verdict 'not supportable'. BBC News, 23 June 2012 supports |
| R | Hodges judges it more credible that Turing ended his own life and arranged matters so that it could be taken for an accident. A biographer's interpretation; it conflicts with CLM-0010. |
disputed | Hodges A. Alan Turing (overview biography, revised from the Oxford Dictionary of National Biography entry) supports Hodges A. The Alan Turing Internet Scrapbook: Defiant until death supports |
| D | On 10 September 2009 the Prime Minister apologised on behalf of the British government, calling his treatment inhumane and describing his sentence as chemical castration by a series of injections of female hormones, accepted as the alternative to prison. | confirmed | Gordon Brown issues apology for treatment of Alan Turing supports |
| D | On 24 December 2013 he received a posthumous royal pardon; the Justice Secretary called the conviction unjust and discriminatory, and the Prime Minister said the sentence of chemical castration had caused physical and emotional damage. | confirmed | Royal pardon for WW2 code-breaker Dr Alan Turing supports |
| R | The roster lists depression as a primary condition; the sources read document his prosecution, the hormone treatment, and his decision to seek Jungian analysis, but record no diagnosis of depression, so a depressive illness is a retrospective interpretation. Retrospective and uncertain; it must not be read as a documented diagnosis. |
possible | HISTMED Master Roster v3 supports Hodges A. The Alan Turing Internet Scrapbook: Defiant until death supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Bilateral gynecomastia, tender, about 4 cm of firm glandular tissue behind each nipple, after a year of high-dose estrogen; synthetic modern diagnosis linked to the documented breast growth from his hormone treatment | active | confirmed | both_with_link | CLM-0005 |
| S | Suppressed testosterone and gonadotropins from exogenous estrogen (drug-induced hypogonadotropic hypogonadism), with low libido, erectile difficulty, and fatigue | resolved | confirmed | active | CLM-0003 |
| S | Adverse effects of high-dose estrogen given for a year without free and informed consent, as the alternative to imprisonment | active | confirmed | both_with_link | CLM-0003, CLM-0004, CLM-0005, CLM-0012, CLM-0013 |
| S | Major depressive disorder, single episode, moderate, after prosecution and coerced hormone treatment; synthetic modern diagnosis (no depression diagnosis is documented in his lifetime) | active | confirmed | both_with_link | CLM-0006, CLM-0014 |
| S | Vitamin D insufficiency (25-hydroxyvitamin D 22 ng/mL) | resolved | confirmed | active | |
| S | Right lateral ankle sprain while trail running, able to bear weight, Ottawa ankle rules negative; resolved | resolved | confirmed | active |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 2026-04-14 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 15 | http://loinc.org · 44261-6 |
| S | 2026-04-14 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 8 | http://loinc.org · 70274-6 |
| S | 2026-04-14 | Total score [AUDIT-C] | 2 | http://loinc.org · 75626-2 |
| S | 2026-04-14 | Testosterone [Mass/volume] in Serum or Plasma | 112 ng/dL (low) Reference 264-916 ng/dL |
http://loinc.org · 2986-8 |
| S | 2026-04-14 | Estradiol (E2) [Mass/volume] in Serum or Plasma | 148 pg/mL (high) Reference 7.6-42.6 pg/mL |
http://loinc.org · 2243-4 |
| S | 2026-04-14 | Lutropin [Units/volume] in Serum or Plasma | 0.3 m[IU]/mL (low) Reference 1.7-8.6 m[IU]/mL |
http://loinc.org · 10501-5 |
| S | 2026-04-14 | Follitropin [Units/volume] in Serum or Plasma | 0.4 m[IU]/mL (low) Reference 1.5-12.4 m[IU]/mL |
http://loinc.org · 15067-2 |
| S | 2026-04-14 | Sex hormone binding globulin [Moles/volume] in Serum or Plasma | 88 nmol/L (high) Reference 16.5-55.9 nmol/L |
http://loinc.org · 13967-5 |
| S | 2026-04-14 | Prolactin [Mass/volume] in Serum or Plasma | 21.6 ng/mL (high) Reference 4-15.2 ng/mL |
http://loinc.org · 2842-3 |
| S | 2026-04-14 | Choriogonadotropin.beta subunit [Units/volume] in Serum or Plasma | 1 m[IU]/mL Reference <=3 m[IU]/mL |
http://loinc.org · 21198-7 |
| S | 2026-04-14 | Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma | 2.6 ng/mL Reference <=8.3 ng/mL |
http://loinc.org · 1834-1 |
| S | 2026-04-14 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 U/L Reference 7-55 U/L |
http://loinc.org · 1742-6 |
| S | 2026-04-14 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 U/L Reference 8-48 U/L |
http://loinc.org · 1920-8 |
| S | 2026-04-14 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 mg/dL Reference 0.1-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 2026-04-14 | Creatinine [Mass/volume] in Serum or Plasma | 0.96 mg/dL Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-04-14 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 102 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-04-14 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 mIU/L Reference 0.4-4 mIU/L |
http://loinc.org · 3016-3 |
| S | 2026-04-14 | Hemoglobin [Mass/volume] in Blood | 13 g/dL (low) Reference 13.2-16.6 g/dL |
http://loinc.org · 718-7 |
| S | 2026-04-14 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 22 ng/mL (low) Reference 30-100 ng/mL |
http://loinc.org · 62292-8 |
| S | 2026-04-28 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 14 | http://loinc.org · 44261-6 |
| S | 2026-04-28 | Estradiol (E2) [Mass/volume] in Serum or Plasma | 46 pg/mL (high) Reference 7.6-42.6 pg/mL |
http://loinc.org · 2243-4 |
| S | 2026-04-28 | Lutropin [Units/volume] in Serum or Plasma | 0.9 m[IU]/mL (low) Reference 1.7-8.6 m[IU]/mL |
http://loinc.org · 10501-5 |
| S | 2026-06-09 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 12 | http://loinc.org · 44261-6 |
| S | 2026-06-09 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 6 | http://loinc.org · 70274-6 |
| S | 2026-06-09 | Testosterone [Mass/volume] in Serum or Plasma | 238 ng/dL (low) Reference 264-916 ng/dL |
http://loinc.org · 2986-8 |
| S | 2026-06-09 | Estradiol (E2) [Mass/volume] in Serum or Plasma | 26 pg/mL Reference 7.6-42.6 pg/mL |
http://loinc.org · 2243-4 |
| S | 2026-06-09 | Lutropin [Units/volume] in Serum or Plasma | 2.4 m[IU]/mL Reference 1.7-8.6 m[IU]/mL |
http://loinc.org · 10501-5 |
| S | 2026-06-09 | Follitropin [Units/volume] in Serum or Plasma | 3.1 m[IU]/mL Reference 1.5-12.4 m[IU]/mL |
http://loinc.org · 15067-2 |
| S | 2026-06-09 | Prolactin [Mass/volume] in Serum or Plasma | 12.4 ng/mL Reference 4-15.2 ng/mL |
http://loinc.org · 2842-3 |
| S | 2026-06-09 | Hemoglobin [Mass/volume] in Blood | 13.6 g/dL Reference 13.2-16.6 g/dL |
http://loinc.org · 718-7 |
| S | 2026-08-04 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | http://loinc.org · 44261-6 |
| S | 2026-08-04 | Testosterone [Mass/volume] in Serum or Plasma | 452 ng/dL Reference 264-916 ng/dL |
http://loinc.org · 2986-8 |
| S | 2026-08-04 | Lutropin [Units/volume] in Serum or Plasma | 4.8 m[IU]/mL Reference 1.7-8.6 m[IU]/mL |
http://loinc.org · 10501-5 |
| S | 2026-08-04 | Follitropin [Units/volume] in Serum or Plasma | 5.2 m[IU]/mL Reference 1.5-12.4 m[IU]/mL |
http://loinc.org · 15067-2 |
| S | 2026-08-04 | Hemoglobin [Mass/volume] in Blood | 14.4 g/dL Reference 13.2-16.6 g/dL |
http://loinc.org · 718-7 |
| S | 2026-10-06 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | http://loinc.org · 44261-6 |
| S | 2026-10-06 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 3 | http://loinc.org · 70274-6 |
| S | 2026-10-06 | Testosterone [Mass/volume] in Serum or Plasma | 536 ng/dL Reference 264-916 ng/dL |
http://loinc.org · 2986-8 |
| S | 2026-10-06 | Estradiol (E2) [Mass/volume] in Serum or Plasma | 24 pg/mL Reference 7.6-42.6 pg/mL |
http://loinc.org · 2243-4 |
| S | 2026-10-06 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 38 ng/mL Reference 30-100 ng/mL |
http://loinc.org · 62292-8 |
| S | 2026-10-20 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | http://loinc.org · 44261-6 |
| S | 2026-10-20 | Total score [AUDIT-C] | 2 | http://loinc.org · 75626-2 |
| S | 2026-10-20 | Cholesterol [Mass/volume] in Serum or Plasma | 182 mg/dL Reference <=199 mg/dL |
http://loinc.org · 2093-3 |
| S | 2026-10-20 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 62 mg/dL Reference >=40 mg/dL |
http://loinc.org · 2085-9 |
| S | 2026-10-20 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 104 mg/dL Reference <=129 mg/dL |
http://loinc.org · 13457-7 |
| S | 2026-10-20 | Triglyceride [Mass/volume] in Serum or Plasma | 80 mg/dL Reference <=149 mg/dL |
http://loinc.org · 2571-8 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 2026-04-14 | Body height | 178 cm | 8302-2 | S |
| 2026-04-14 | Body weight | 71.4 kg | 29463-7 | S |
| 2026-04-14 | Body mass index (BMI) [Ratio] | 22.5 kg/m2 | 39156-5 | S |
| 2026-04-14 | Systolic blood pressure | 122 mm[Hg] | 8480-6 | S |
| 2026-04-14 | Diastolic blood pressure | 76 mm[Hg] | 8462-4 | S |
| 2026-04-14 | Heart rate | 64 /min | 8867-4 | S |
| 2026-04-14 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-04-14 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-04-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2026-04-28 | Body height | 178 cm | 8302-2 | S |
| 2026-04-28 | Body weight | 71 kg | 29463-7 | S |
| 2026-04-28 | Body mass index (BMI) [Ratio] | 22.4 kg/m2 | 39156-5 | S |
| 2026-04-28 | Systolic blood pressure | 120 mm[Hg] | 8480-6 | S |
| 2026-04-28 | Diastolic blood pressure | 74 mm[Hg] | 8462-4 | S |
| 2026-04-28 | Heart rate | 62 /min | 8867-4 | S |
| 2026-04-28 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-04-28 | Body temperature | 36.5 Cel | 8310-5 | S |
| 2026-04-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2026-06-09 | Body height | 178 cm | 8302-2 | S |
| 2026-06-09 | Body weight | 70.1 kg | 29463-7 | S |
| 2026-06-09 | Body mass index (BMI) [Ratio] | 22.1 kg/m2 | 39156-5 | S |
| 2026-06-09 | Systolic blood pressure | 118 mm[Hg] | 8480-6 | S |
| 2026-06-09 | Diastolic blood pressure | 74 mm[Hg] | 8462-4 | S |
| 2026-06-09 | Heart rate | 58 /min | 8867-4 | S |
| 2026-06-09 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-06-09 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-06-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2026-08-04 | Body height | 178 cm | 8302-2 | S |
| 2026-08-04 | Body weight | 69.3 kg | 29463-7 | S |
| 2026-08-04 | Body mass index (BMI) [Ratio] | 21.9 kg/m2 | 39156-5 | S |
| 2026-08-04 | Systolic blood pressure | 124 mm[Hg] | 8480-6 | S |
| 2026-08-04 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2026-08-04 | Heart rate | 60 /min | 8867-4 | S |
| 2026-08-04 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-08-04 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-08-04 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2026-10-06 | Body height | 178 cm | 8302-2 | S |
| 2026-10-06 | Body weight | 68.6 kg | 29463-7 | S |
| 2026-10-06 | Body mass index (BMI) [Ratio] | 21.7 kg/m2 | 39156-5 | S |
| 2026-10-06 | Systolic blood pressure | 118 mm[Hg] | 8480-6 | S |
| 2026-10-06 | Diastolic blood pressure | 72 mm[Hg] | 8462-4 | S |
| 2026-10-06 | Heart rate | 54 /min | 8867-4 | S |
| 2026-10-06 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-10-06 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-10-06 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2026-08-25 | Body height | 178 cm | 8302-2 | S |
| 2026-08-25 | Body weight | 69 kg | 29463-7 | S |
| 2026-08-25 | Body mass index (BMI) [Ratio] | 21.8 kg/m2 | 39156-5 | S |
| 2026-08-25 | Systolic blood pressure | 126 mm[Hg] | 8480-6 | S |
| 2026-08-25 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 2026-08-25 | Heart rate | 70 /min | 8867-4 | S |
| 2026-08-25 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-08-25 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-08-25 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2026-10-20 | Body height | 178 cm | 8302-2 | S |
| 2026-10-20 | Body weight | 68.5 kg | 29463-7 | S |
| 2026-10-20 | Body mass index (BMI) [Ratio] | 21.6 kg/m2 | 39156-5 | S |
| 2026-10-20 | Systolic blood pressure | 116 mm[Hg] | 8480-6 | S |
| 2026-10-20 | Diastolic blood pressure | 72 mm[Hg] | 8462-4 | S |
| 2026-10-20 | Heart rate | 54 /min | 8867-4 | S |
| 2026-10-20 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-10-20 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-10-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Occupation: mathematician and computer scientist; moved here three months ago to a university research post, after a criminal conviction abroad for a consensual relationship with another adult man under a law that criminalizes sex between men
- S Sexual orientation: gay; pronouns he/him; lives alone; not in a relationship now; has one or two close friends here and others abroad
- S Long-distance runner, usually 40 to 50 km a week; has run less in recent months and stopped changing at the running club because of his chest
- S Never smoker; two or three drinks a week; no drug use
- S Supports: absorbing research work, running, a few trusted friends, and a willingness to talk to a therapist; no firearms in the home
Functional status
- S At intake, working full days but sleeping badly, avoiding the running club changing room, and seeing friends less
Mental status
- S Tall, lean, casually dressed; slightly hesitant speech that becomes quick and precise on technical subjects; wry humor; cooperative
- S Mood "flattened, and angry about what was done to me"; affect constricted, reactive; thought process linear; no suicidal ideation, intent, or plan; no psychotic features; insight and judgment good
Structured safety assessment
This assessment is synthetic and does not convert historical behavior into a present-day fact.
Allergies and medications
Allergies
- S No known allergy
Medications
- S Cholecalciferol 1,000 units (25 mcg) oral tablet, one tablet by mouth daily
- S Bupropion extended-release 150 mg oral tablet, one tablet by mouth each morning
- S Ibuprofen 400 mg oral tablet, one tablet by mouth up to three times a day with food for no more than 5 days
Procedures and immunizations
Procedures
- S Scrotal ultrasound for gynecomastia workup: testes about 15 mL each, homogeneous, no mass; no varicocele
- S Advance care planning conversation, about 20 minutes
Immunizations
- S 2025-10-14: Influenza vaccine, 2025-2026 season
- S 2021-05-11: Tdap vaccine
- S 2026-10-20: Influenza vaccine, 2026-2027 season
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
- D 31 March 1952: Year of oestrogen treatment (probably stilboestrol) accepted as the alternative to prison after his conviction for gross indecency (CLM-0003, CLM-0004)
- D 1952: Breast growth attributed to the hormone treatment, which he is known to have mentioned once (CLM-0005)
- D November 1952: Decided to see a psychiatrist again and began Jungian analysis (CLM-0006)
Family history
No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| Testosterone, LH, and FSH back in the reference range within six months of the last estrogen dose, without testosterone therapy | 2026-08-04 | completed | Testosterone 452 ng/dL with normal LH and FSH at sixteen weeks |
| Breast tenderness gone and gynecomastia reduced; a surgical opinion offered if it persists and troubles him | 2026-10-06 | active | Tenderness gone by six months; small residual glandular tissue; watchful waiting to twelve months |
| Depression response (PHQ-9 down by at least 50 percent) by sixteen weeks, then remission (PHQ-9 below 5) | 2026-10-06 | completed | PHQ-9 7 at sixteen weeks (down 53 percent) and 4 at six months |
| Back to running about 40 km a week and changing at his club again | 2026-10-06 | completed | Running 40 km a week and back with the club by six months |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Consent first: every examination, test, and treatment is explained and offered, and he may decline any of it; intimate examinations only with his agreement at each step and with a chaperone offered. The estrogen he was given as a condition of avoiding prison was not freely consented treatment, and no further doses will be given | completed | GL-APA-SM-2021, GL-EAA-GM-2019, GL-ES-HYPOGONAD-2018 |
| Gynecomastia workup: breast and testicular examination; testosterone, estradiol, LH, FSH, prolactin, SHBG, hCG, AFP, liver, kidney, and thyroid tests today; scrotal ultrasound; breast ultrasound only if the examination becomes equivocal | completed | GL-EAA-GM-2019, GL-ES-HYPOGONAD-2018 |
| Endocrinology consultation to confirm that the estrogen explains the findings and to advise on recovery of the gonadal axis, testosterone therapy, bone health, and surgery | completed | GL-EAA-GM-2019, GL-ES-HYPOGONAD-2018 |
| Watchful waiting for the gynecomastia after the estrogen stops; testosterone, estradiol, LH, and FSH every six to eight weeks until normal; no testosterone therapy while the axis is recovering; a surgical opinion if gynecomastia persists about twelve months and troubles him | completed | GL-EAA-GM-2019, GL-ES-HYPOGONAD-2018 |
| Bone health: vitamin D replacement, calcium from food, continued running and strength work; bone density scan only if hypogonadism persists beyond six months or a fracture occurs | completed | GL-EAA-GM-2019, GL-ES-HYPOGONAD-2018, GL-ES-OSTEO-MEN-2012 |
| Weekly psychotherapy with a gay-affirming clinic psychologist for about 16 sessions, addressing the prosecution, the coerced treatment, and minority stress; an antidepressant offered and declined for now, to be reconsidered if the PHQ-9 has not fallen by half at about eight weeks | completed | GL-MDD-2022, GL-CMID-2026, GL-APA-SM-2021 |
| Collaborative safety plan with warning signs, coping steps, people to contact, the clinic number, and the 988 Suicide & Crisis Lifeline; suicide-risk review and PHQ-9 at every visit | completed | GL-SUICIDE-2024, GL-CMID-2026 |
| Sexual health as routine adult care: HIV and STI testing and a PrEP discussion offered at his preventive visit, with his consent; libido and erectile function reviewed as testosterone recovers | completed | GL-CDC-STI-2021, GL-USPSTF-PREP-2023, GL-APA-SM-2021 |
| Affirming practice: his orientation, name, and pronouns recorded as he chooses; his records shared only with his consent; a written letter from this clinic, at his request, confirming that the estrogen he was given was not medically indicated | completed | GL-APA-SM-2021 |
| Add bupropion XL 150 mg each morning, chosen by him after an informed discussion of options and side effects; nurse telephone check at two weeks; PHQ-9 and blood pressure at each visit | completed | GL-CMID-2026, GL-MDD-2022 |
Planned encounters
- 2026-04-14 — New-patient primary care visit for breast enlargement, low libido, and low mood after a year of high-dose estrogen given without his consent (ENC-001)
- 2026-04-28 — Two-week follow-up with endocrinology consultation and scrotal ultrasound (ENC-002)
- 2026-06-09 — Eight-week review of hormone recovery and depression treatment (ENC-003)
- 2026-08-04 — Sixteen-week review of hormone recovery and depression treatment (ENC-004)
- 2026-08-25 — Same-day sick visit for a right ankle sprain (ENC-006, unscheduled)
- 2026-10-06 — Six-month review of gynecomastia and depression in continuation treatment (ENC-005)
- 2026-10-20 — Periodic adult preventive visit (ENC-007)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Focused Visit (Follow-up)
- Progress note 04 — Focused Visit (Follow-up)
- Progress note 05 — Sick Visit
- Progress note 06 — Focused Visit (Care-plan review)
- Progress note 07 — Preventive Visit
- Endocrinology referral
- Endocrinology consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Focused Visit (Follow-up) (XML)
- Progress note 04 — Focused Visit (Follow-up) (XML)
- Progress note 05 — Sick Visit (XML)
- Progress note 06 — Focused Visit (Care-plan review) (XML)
- Progress note 07 — Preventive Visit (XML)
- Endocrinology referral (XML)
- Endocrinology consultation (XML)
Sources
| ID | Source | Publisher | Type |
|---|---|---|---|
| SRC-0001 | Hodges A. Alan Turing (overview biography, revised from the Oxford Dictionary of National Biography entry) | Andrew Hodges, The Alan Turing Home Page | biography |
| SRC-0002 | Hodges A. The Alan Turing Internet Scrapbook: Defiant until death | Andrew Hodges, The Alan Turing Home Page | biography |
| SRC-0003 | O'Connor JJ, Robertson EF. Alan Mathison Turing. MacTutor History of Mathematics | University of St Andrews | biography |
| SRC-0004 | Hodges A. The Alan Turing Internet Scrapbook: Non-linear Life | Andrew Hodges, The Alan Turing Home Page | biography |
| SRC-0005 | Pease R. Alan Turing: Inquest's suicide verdict 'not supportable'. BBC News, 23 June 2012 | BBC News | other |
| SRC-0006 | Royal pardon for WW2 code-breaker Dr Alan Turing | UK Ministry of Justice (GOV.UK) | government |
| SRC-0007 | Gordon Brown issues apology for treatment of Alan Turing | The University of Manchester | other |
| SRC-0008 | HISTMED Master Roster v3 | The Human Record project | other |
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check the gynecomastia workup and watchful waiting, recovery of the gonadal axis without testosterone therapy, the bone-health plan, the depression treatment and safety review at every visit, routine sexual health care, and the recorded deviation. |
| provenance review | not_started | Hodges's biography pages, MacTutor, a BBC report, a GOV.UK press release, and a University of Manchester news item logged. The prosecution, the hormone treatment, Jungian analysis, and the death and verdict are D; depression and both readings of his death are R. The tablet-and-implant account of the treatment was not verified. |
| safe messaging review | not_started | Safety assessment is synthetic with no current ideation; the disputed circumstances of his death are recorded only as history, in plain terms and without method detail, and are not echoed in the modern episode. Sexual orientation is recorded respectfully and never as a problem. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.